ICCC IMMUCELL CORP /DE/
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 811641 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY19.6%
TTM net income YoY-19.1%
TTM EPS YoY-32.1%
Revenue 3-yr CAGR26.8%
Net income 3-yr CAGR—
Margins
Gross margin40.8%
Operating margin14.5%
Net margin5.7%
FCF margin16.3%
EBITDA margin21.0%
Returns
ROE6.0%
ROA4.2%
ROIC (approx.)13.8%
Asset turnover0.73x
Leverage & solvency
Liabilities / assets31.7%
Debt / equity0.24x
Current ratio4.61x
Interest coverage12.19x
Cash quality & payout
Operating cash flow / net income4.17x
Accruals ratio-13.2%
Payout ratio—
Capex / revenue7.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $27.64M | $26.49M |
| Cost of revenue | $16.20M | $18.55M |
| Gross profit | $11.45M | $7.94M |
| R&D expense | $3.04M | $3.90M |
| SG&A expense | $3.20M | $2.22M |
| Operating income | $1.65M | -$1.64M |
| Interest expense | $493,384 | $568,725 |
| Pretax income | -$1.03M | -$2.15M |
| Income tax | $11,570 | $10,056 |
| Net income | -$1.04M | -$2.16M |
| EBITDA | $4.43M | $1.09M |
| EPS (basic) | -0.12 | -0.26 |
| EPS (diluted) | -0.12 | -0.26 |
| Weighted avg. shares (diluted) | 9.03M | 8.17M |
| Balance sheet | ||
| Cash & equivalents | $3.81M | $3.76M |
| Receivables | $3.42M | $3.77M |
| Inventory | $9.27M | $7.11M |
| Current assets | $16.94M | $15.04M |
| PP&E, net | $21.07M | $25.35M |
| Goodwill | $95,557 | $95,557 |
| Intangibles | $0 | $19,104 |
| Total assets | $42.53M | $45.10M |
| Current liabilities | $3.98M | $4.41M |
| Short-term debt | $1.61M | $1.50M |
| Long-term debt | $7.49M | $9.04M |
| Total debt | $9.10M | $10.54M |
| Total liabilities | $15.48M | $17.58M |
| Shareholders' equity | $27.06M | $27.52M |
| Net debt | $5.29M | $6.78M |
| Shares outstanding | 9.05M | 8.98M |
| Cash flow statement | ||
| Operating cash flow | $2.48M | $357,903 |
| Capital expenditure | $1.25M | $465,725 |
| Free cash flow | $1.22M | -$107,822 |
| Investing cash flow | -$1.21M | -$461,225 |
| Financing cash flow | -$1.21M | $2.88M |
| Depreciation & amortization | $2.78M | $2.73M |
| Stock-based compensation | $295,871 | $325,551 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.